Smoking causes cancer, but it could protect against Parkinson’s disease. This has been demonstrated by various epidemiological studies, according to which there exists an inverse relationship between smoking and the probability of developing Parkinson’s disease.
The link is not however 100% clear, as some smokers develop the illness nevertheless. The hypothesis is that there is a genetic predisposition that, in combination with environmental factors, can trigger the disease. Taking this as its starting point, a team from the Mayo Clinic in Rochester, MN (USA) has carried out a study on a sample of 1228 subjects. The team includes Maurizio Facheris, a researcher at the Institute of Genetic Medicine at the European Academy of Bozen/Bolzano (EURAC), previous Research Fellow at the prestigious American clinic and who co-ordinated the study.
The researchers hypothesized that the variation may be due to pharmacogenetic effects and that nicotine might have neuroprotective properties for certain individuals.
“We asked the interviewees to tell us about their relationship with smoking and then compared this data with the presence or absence of variations in the gene CYP2A6, which encodes the enzyme responsible for metabolising nicotine”, says EURAC researcher Maurizio Facheris, neurologist at the Department of Neurology of Bozen/Bolzano Central Hospital and main author of the study.
From an analysis of the data, it emerges that the presence of a particular variant of the gene, when combined with smoking, considerably reduces the risk of contracting Parkinson’s disease. It remains to be clarified whether the protection against the disease is provided by the particular variant of gene CYP2A6 or by the presence of cotinine, the substance into which nicotine is transformed through the action of the gene. “If this second hypothesis is confirmed, producing a cotinine-based drug would be a means to reduce exposure to the disease”, explains Maurizio Facheris.The study opens up interesting scenarios in the field of pharmacogenetics, a discipline that holds that variations in different patients’ response to pharmacological treatment depends on genetic factors. Under this view, analysing the patients’ DNA will allow us to predict their reaction to a particular drug and thus enable the development of personalised medicines.
The study was presented at Toronto on the occasion of the annual convention of the American Academy of Neurology, and was selected as among the top 5% of over 2,000 articles received. It was the first study of its kind to be presented.
Laura Defranceschi | idw
Diagnoses: When Are Several Opinions Better Than One?
19.07.2016 | Max-Planck-Institut für Bildungsforschung
High in calories and low in nutrients when adolescents share pictures of food online
07.04.2016 | University of Gothenburg
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences